Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-α-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability

Teratogenesis Carcinogenesis and Mutagenesis

Volumn , Issue SUPPL. 1, 2003, Pages 1-11

  Kruszewski, Marcin ^a,b   Bouzyk, Elzbieta ^a   Oldak, Tomasz ^b   Samochocka, Krystyna ^b,c   Fuks, Leon ^a   Lewandowski, Włodzimierz ^d,e   Fokt, Izabela ^f   Priebe, Waldemar ^f  

^a INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

^d BIALYSTOK UNIVERSITY OF TECHNOLOGY   (Poland)

^e NATIONAL MEDICINES INSTITUTE   (Poland)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cis platin; Comet assay; Cytotoxicity; DNA crosslinks; L5178Y cells; Single cell gel electrophoresis

Indexed keywords

CISPLATIN; DOUBLE STRANDED DNA; METHYL 3,4 DIAMINE 2,3,4,6 TETRADEOXY ALPHA LEVO LYXOHEXOPYRANOSIDE; PALLADIUM CHLORIDE; PALLADIUM COMPLEX; PYRANOSIDE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL GROWTH; CELL SUSPENSION; COMET ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DOSE RESPONSE; EXCISION REPAIR; GENOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; STUDENT T TEST; TOXICITY; X IRRADIATION;

EID: 0037288309     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/tcm.10046     Document Type: Conference Paper

References (34)

1. Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med 1979;300:289-291.
2. Lokich J. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? Cancer Invest 2001;19:756-760.
3. Khokhar AR, Al-Baker S, Perez-Soler R. Toxicity and anti-tumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles. Anticancer Drug Des 1988;3:177-184.
4. Kopf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 1994;47:1-16.
5. Farrell N, Qu Y, Feng L, Van Houten B. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of cis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 1990;29:9522-9531.
6. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E. Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem-Biol Interact 1995;95:109-126.
7. Di Marco A, Casazza AM, Giuliani F, Pratesi G, Arcamone F, Bernardi L, Franchi G, Giardino P, Patelli B, Penco S. Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4′-epiadriamycin. Cancer Treat Rep 1978;62:375-380.
8. Zunino F, Savi G, Pasini A. Synthesis and antitumor activity of a platinum (II)-doxorubicin complex. Cancer Chemother Pharmacol 1986;18:180-182.
9. Zunino F, Pratesi G, Formelli F, Pasini A. Evaluation of a platinum-doxorubicin complex in experimental tumor systems. Invest New Drugs 1990;8:341-345.
10. Horton D, Priebe W, Sznaidman, ML, Varela O. Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine. J Antibiot (Tokyo) 1993;46:1720-1730.
11. Tsubomura T, Ogawa M, Yano S, Kobayashi K, Sakurai T, Yoshikawa S. Highly active antitumor platinum(II) complexes of amino sugars. Inorg Chem 1990;29:2622-2626.
12. 2O. Chem Commun 1986;459-460.
13. Kolar C, Dehmel K, Moldenhauer H, Gerken M. Semisynthetic β-rhodomycins: a new approach to the synthesis of 4-O-methyl-β-rhodomycins. J Carbohydrate Chemistry 1990;9:873-890.
14. Szumiel I. Response of two strains of L5178Y cells to cis- dichlorobis(cyclopentylamine)platinum(II). I. Cross-sensitivity to cis- PAD and UV light. Chem-Biol Interact 1979;24:51-72.
15. Wojewodzka M, Kruszewski M, Iwanenko T, Collins AR, Szumiel I. Application of the comet assay for monitoring DNA damage in workers exposed to chronic low-dose irradiation. I. Strand breakage. Mutat Res 1998;416:21-35.
16. Merk O, Speit G. Significance of formaldehyde-induced DNA-protein crosslinks for mutagenesis. Environ Mol Mutagen 1998;32:260-268.
17. Turchi JJ, Henkels KM, Zhou Y. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. Nucleic Acids Res 2000;28:4634-4641.
18. Kruszewski M, Zaim J, Gradzka I, Szumiel I. Comparison of the effects of bleomycin and ionizing radiation in two sublines of murine lymphoma L5178Y. Nukleonika 2001;46:81-86.
19. Bouzyk E, Iwanenko T, Jarocewicz N, Kruszewski M, Sochanowicz B, Szumiel I. Antioxidant defense system in differentially hydrogen peroxide sensitive L5178Y sublines. Free Radic Biol Med 1997;22:697-704.
20. Walicka M, Godlewska E, Kleczkowska H. Effect of UVC and araC on L5178Y-R and L5178Y-S cells. Nucleoid sedimentation. Acta Biochim Pol 1987;34:345-355.
21. Wlodek D, Hittelman WN. The repair of double-strand DNA breaks correlates with radiosensitivity of L5178Y-S and L5178Y-R cells. Radiat Res 1987;112:146-155.
22. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 2000;95:2975-2982.
23. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 1986;25:3912-3915.
24. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999;77:71-81.
25. Turchi JJ, Henkels KM, Hermanson IL, Patrick SM. Interactions of mammalian proteins with cisplatin-damaged DNA. J Inorg Biochem 1999;77:83-87.
26. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001;478:1-21.
27. Samochocka K, Kruszewski M, Szumiel I. Interaction of some organic platinum (II) complexes with L5178Y-R and L5178Y-S cells. Chem-Biol Interact 1997;105:145-155.
28. Buraczewska I, Bouzyk E, Kuduk-Jaworska J, Waszkiewicz K, Gasinska A, Szumiel I. Differential anti-proliferative properties of novel hydroxydicarboxylatoplatinum(II) complexes with high or low reactivity with thiols. Chem-Biol Interact 2000;129:297-315.
29. Turchi JJ, Henkels K. Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J Biol Chem 1996;271:13861-13867.
30. Turchi JJ, Patrick SM, Henkels KM. Mechanism of DNA-dependent protein kinase inhibition by cis- diamminedichloroplatinum(II)-damaged DNA. BiochemistryOK 1997;36:7586-7593.
31. Jackson SP, Jeggo PA. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem Sci 1995;20:412-415.
32. Frit P, Canitrot Y, Muller C, Foray N, Calsou P, Marangoni E, Bourhis J, Salles B. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 1999;56:141-146.
33. Kruszewski M, Wojewodzka M, Iwanenko T, Szumiel I, Okuyama A. Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat Res 1998;409:31-36.
34. Matesanz AI, Perez JM, Navarro P, Moreno JM, Colacio E, Souza P. Synthesis and characterization of novel palladium(II) complexes of bis(thiosemicarbazone). Structure, cytotoxic activity and DNA binding of Pd(II)-benzyl bis(thiosemicarbazonate). J Inorg Biochem 1999;76:29-37.